Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non-small cell lung cancer: A real-world study

被引:1
作者
Wei, Jingwen [1 ,2 ]
Shi, Zheng [1 ,2 ]
Song, Zhengbo [1 ,2 ,3 ]
机构
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Clin Trial, Canc Hosp, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Postgrad Training Base Alliance, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Clin Trial, Canc Hosp, 1 Banshan East Rd, Hangzhou 310022, Peoples R China
关键词
catheter drainage; intrapericardial administration; malignant pericardial effusion; non-small cell lung cancer; PRIMARY MANAGEMENT; INTRACAVITARY BLEOMYCIN; INSTILLATION; PROGNOSIS;
D O I
10.1002/cam4.6404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Malignant pericardial effusion (MPE) is a serious complication of cancer that can be potentially deadly. It usually occurs in advanced or terminal stages of the disease, and as a result, patients with MPE often have a poor prognosis. There is a limited amount of research available that directly compares the effectiveness and safety of intrapericardial drug administration following pericardial drainage versus catheter drainage alone in non-small cell lung cancer (NSCLC) patients who have MPE.Methods: We retrospectively included 86 patients with NSCLC with MPE at Zhejiang Cancer Hospital. Survival and recurrence estimates were determined with the Kaplan-Meier method.Results: We divided the 86 patients with NSCLC into two groups: a pericardial drainage group (34 out of 86, 39.5%) and an intrapericardial administration group (52 out of 86, 60.5%). The response rates were 70.6% and 76.9% (p = 0.510), respectively. The median OS was 132.0 and 234.0 days (p = 0.579), respectively. The median time to recurrent drainage was 43.0 and 104.0 days (p = 0.170), respectively. The incidence of adverse events (AEs) was 44.1% and 61.5% (p = 0.113), respectively. The most frequent AEs were pain (27.9%) and fever (24.4%). Additionally, two patients in the intrapericardial administration group died of cardiac arrest.Conclusions: Compared with catheter drainage alone, intrapericardial medication infusion during catheter drainage did not have significantly different effects. AEs require close monitoring and management.
引用
收藏
页码:18211 / 18218
页数:8
相关论文
共 21 条
[1]   Effectiveness and prognosis of initial pericardiocentesis in the primary management of malignant pericardial effusion [J].
Apodaca-Cruz, Angel ;
Villarreal-Garza, Cynthia ;
Torres-Avila, Beatriz ;
Torres, Jorge ;
Meneses, Abelardo ;
Flores-Estrada, Diana ;
Lara-Medina, Fernando ;
Arrieta, Oscar .
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2010, 11 (02) :154-161
[2]   Malignant Pericardial Effusion [J].
Burazor, I. ;
Imazio, M. ;
Markel, G. ;
Adler, Y. .
CARDIOLOGY, 2013, 124 (04) :224-232
[3]   Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation [J].
Defruyt, Loran ;
Ozpak, Emine ;
Gevaert, Sofie ;
De Buyzere, Marc ;
Vandecasteele, Els ;
De Pauw, Michel .
ACTA CLINICA BELGICA, 2022, 77 (01) :51-58
[4]   Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion [J].
Gornik, HL ;
Gerhard-Herman, M ;
Beckman, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5211-5216
[5]   Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study [J].
Imai, Hisao ;
Kaira, Kyoichi ;
Masubuchi, Ken ;
Minato, Koichi .
CURRENT ONCOLOGY, 2022, 29 (01) :163-172
[6]   Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer [J].
Kaira, K ;
Takise, A ;
Kobayashi, G ;
Utsugi, M ;
Horie, T ;
Mori, T ;
Imai, H ;
Inazawa, M ;
Mori, M .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (02) :57-60
[7]   PERCUTANEOUS PERICARDIAL CATHETER DRAINAGE - REPORT OF 42 CONSECUTIVE CASES [J].
KOPECKY, SL ;
CALLAHAN, JA ;
TAJIK, AJ ;
SEWARD, JB .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 58 (07) :633-635
[8]   Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study [J].
Kotake, Mie ;
Imai, Hisao ;
Kaira, Kyoichi ;
Fujisawa, Tomomi ;
Yanagita, Yasuhiro ;
Minato, Koichi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) :655-660
[9]   A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) [J].
Kunitoh, H. ;
Tamura, T. ;
Shibata, T. ;
Imai, M. ;
Nishiwaki, Y. ;
Nishio, M. ;
Yokoyama, A. ;
Watanabe, K. ;
Noda, K. ;
Saijo, N. .
BRITISH JOURNAL OF CANCER, 2009, 100 (03) :464-469
[10]   Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade [J].
Liu, G ;
Crump, M ;
Goss, PE ;
Dancey, J ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3141-3147